{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:56:05Z","timestamp":1777524965819,"version":"3.51.4"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":1868,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Research in the last decade strongly suggests that mesenchymal stem cell (MSC)-mediated therapeutic benefits are mainly due to their secretome, which has been proposed as a possible therapeutic tool for the treatment of Parkinson's disease (PD). Indeed, it has been shown that the MSC secretome increases neurogenesis and cell survival, and has numerous neuroprotective actions under different conditions. Additionally, using dynamic culturing conditions (through computer-controlled bioreactors) can further modulate the MSC secretome, thereby generating a more potent neurotrophic factor cocktail (i.e., conditioned medium). In this study, we have characterized the MSC secretome by proteomic-based analysis, investigating its therapeutic effects on the physiological recovery of a 6-hydroxidopamine (6-OHDA) PD rat model. For this purpose, we injected MSC secretome into the substantia nigra (SNc) and striatum (STR), characterizing the behavioral performance and determining histological parameters for injected animals versus untreated groups. We observed that the secretome potentiated the increase of dopaminergic neurons (i.e., tyrosine hydroxylase-positive cells) and neuronal terminals in the SNc and STR, respectively, thereby supporting the recovery observed in the Parkinsonian rats\u2019 motor performance outcomes (assessed by rotarod and staircase tests). Finally, proteomic characterization of the MSC secretome (through combined mass spectrometry analysis and Bioplex assays) revealed the presence of important neuroregulatory molecules, namely cystatin C, glia-derived nexin, galectin-1, pigment epithelium-derived factor, vascular endothelial growth factor, brain-derived neurotrophic factor, interleukin-6, and glial cell line-derived neurotrophic factor. Overall, we concluded that the use of human MSC secretome alone was able to partially revert the motor phenotype and the neuronal structure of 6-OHDA PD animals. This indicates that the human MSC secretome could represent a novel therapeutic for the treatment of PD.<\/jats:p>","DOI":"10.5966\/sctm.2016-0071","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T02:09:11Z","timestamp":1474596551000},"page":"634-646","source":"Crossref","is-referenced-by-count":177,"title":["Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease"],"prefix":"10.1093","volume":"6","author":[{"given":"F\u00e1bio G.","family":"Teixeira","sequence":"first","affiliation":[{"name":"a Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal"},{"name":"b ICVS\/3B's - PT Government Associate Laboratory, Braga\/Guimar\u00e3es, Portugal"}]},{"given":"Miguel M.","family":"Carvalho","sequence":"additional","affiliation":[{"name":"a Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal"},{"name":"b ICVS\/3B's - PT Government Associate Laboratory, Braga\/Guimar\u00e3es, Portugal"}]},{"given":"Krishna M.","family":"Panchalingam","sequence":"additional","affiliation":[{"name":"c Pharmaceutical Production Research Facility, Department of Chemical and Petroleum Engineering, University of Calgary, Calgary, Alberta, Canada"}]},{"given":"Ana J.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"a Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal"},{"name":"b ICVS\/3B's - PT Government Associate Laboratory, Braga\/Guimar\u00e3es, Portugal"}]},{"given":"B\u00e1rbara","family":"Mendes-Pinheiro","sequence":"additional","affiliation":[{"name":"a Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal"},{"name":"b ICVS\/3B's - PT Government Associate Laboratory, Braga\/Guimar\u00e3es, Portugal"}]},{"given":"Sandra","family":"Anjo","sequence":"additional","affiliation":[{"name":"d Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"e Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal"}]},{"given":"Bruno","family":"Manadas","sequence":"additional","affiliation":[{"name":"d Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal"},{"name":"f Biocant - Biotechnology Innovation Center, Cantanhede, Portugal"}]},{"given":"Leo A.","family":"Behie","sequence":"additional","affiliation":[{"name":"c Pharmaceutical Production Research Facility, Department of Chemical and Petroleum Engineering, University of Calgary, Calgary, Alberta, Canada"}]},{"given":"Nuno","family":"Sousa","sequence":"additional","affiliation":[{"name":"a Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal"},{"name":"b ICVS\/3B's - PT Government Associate Laboratory, Braga\/Guimar\u00e3es, Portugal"}]},{"given":"Ant\u00f3nio J.","family":"Salgado","sequence":"additional","affiliation":[{"name":"a Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, Braga, Portugal"},{"name":"b ICVS\/3B's - PT Government Associate Laboratory, Braga\/Guimar\u00e3es, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"2022022809300083600_R1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1326-8-14","article-title":"Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits","volume":"8","author":"Carvalho","year":"2013","journal-title":"Mol Neurodegener"},{"key":"2022022809300083600_R2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1602\/neurorx.1.4.382","article-title":"Cell therapy in Parkinson's disease","volume":"1","author":"Lindvall","year":"2004","journal-title":"NeuroRx"},{"key":"2022022809300083600_R3","first-page":"101","article-title":"Motor fluctuations in Parkinson's disease","volume":"3","author":"Weiner","year":"2006","journal-title":"Rev Neurol Dis"},{"key":"2022022809300083600_R4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11064-008-9656-2","article-title":"Oxidative and inflammatory pathways in Parkinson's disease","volume":"34","author":"Miller","year":"2009","journal-title":"Neurochem Res"},{"key":"2022022809300083600_R5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1515\/REVNEURO.2009.20.5-6.347","article-title":"Cell-based therapeutic approaches for Parkinson's disease: Progress and perspectives","volume":"20","author":"Anisimov","year":"2009","journal-title":"Rev Neurosci"},{"key":"2022022809300083600_R6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pneurobio.2006.11.009","article-title":"Advances in the treatment of Parkinson's disease","volume":"81","author":"Singh","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"suppl 3","key":"2022022809300083600_R7","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1002\/mds.22048","article-title":"Levodopa therapy for Parkinson's disease: Challenges and future prospects","volume":"23","author":"Olanow","year":"2008","journal-title":"Mov Disord"},{"issue":"suppl 3","key":"2022022809300083600_R8","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1002\/mds.22061","article-title":"Levodopa\/dopamine replacement strategies in Parkinson's disease\u2013\u2013future directions","volume":"23","author":"Olanow","year":"2008","journal-title":"Mov Disord"},{"issue":"suppl 6","key":"2022022809300083600_R9","first-page":"VI\/44","article-title":"Is levodopa toxic?","volume":"251","author":"M\u00fcller","year":"2004","journal-title":"J Neurol"},{"key":"2022022809300083600_R10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","article-title":"Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration","volume":"61","author":"M\u00fcller","year":"2004","journal-title":"Arch Neurol"},{"key":"2022022809300083600_R11","first-page":"191","article-title":"Advances in the diagnosis, treatment, and understanding of Parkinson's disease and parkinsonism","volume":"3","author":"Weiner","year":"2006","journal-title":"Rev Neurol Dis"},{"key":"2022022809300083600_R12","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: Implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"key":"2022022809300083600_R13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1742-4658.2008.06296.x","article-title":"Parkinson's disease: Levodopa-induced dyskinesia and signal transduction","volume":"275","author":"Santini","year":"2008","journal-title":"FEBS J"},{"key":"2022022809300083600_R14","first-page":"465","article-title":"Update on surgery for Parkinson's disease","volume":"20","author":"Volkmann","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"2022022809300083600_R15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.5114\/aoms.2014.44864","article-title":"The effects of brain stimulation of subthalamic nucleus surgery on gait and balance performance in Parkinson disease. A pilot study","volume":"10","author":"Altu\u011f","year":"2014","journal-title":"Arch Med Sci"},{"key":"2022022809300083600_R16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1586\/14737175.2013.859987","article-title":"New targets for deep brain stimulation treatment of Parkinson's disease","volume":"13","author":"Castrioto","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"2022022809300083600_R17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10072-003-0126-y","article-title":"Six years\u2019 experience in deep brain stimulation in Parkinson's disease: Advantages and limitations of use of neurophysiological intraoperative microreading","volume":"24","author":"Nordera","year":"2003","journal-title":"Neurol Sci"},{"key":"2022022809300083600_R18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11481-007-9074-2","article-title":"Stem cell transplantation: A promising therapy for Parkinson's disease","volume":"2","author":"Wang","year":"2007","journal-title":"J Neuroimmune Pharmacol"},{"key":"2022022809300083600_R19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.neuint.2008.02.003","article-title":"Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease","volume":"52","author":"Bouchez","year":"2008","journal-title":"Neurochem Int"},{"key":"2022022809300083600_R20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/14653240802021330","article-title":"Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease","volume":"10","author":"Levy","year":"2008","journal-title":"Cytotherapy"},{"key":"2022022809300083600_R21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/CBI20090012","article-title":"Intrastriatal grafts of mesenchymal stem cells in adult intact rats can elevate tyrosine hydroxylase expression and dopamine levels","volume":"34","author":"Jin","year":"2009","journal-title":"Cell Biol Int"},{"key":"2022022809300083600_R22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.expneurol.2007.10.011","article-title":"Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease","volume":"210","author":"McCoy","year":"2008","journal-title":"Exp Neurol"},{"key":"2022022809300083600_R23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1634\/stemcells.2005-0053","article-title":"Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: Potential therapeutic application for Parkinsonism","volume":"24","author":"Fu","year":"2006","journal-title":"Stem Cells"},{"key":"2022022809300083600_R24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trsl.2009.07.006","article-title":"Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease","volume":"155","author":"Venkataramana","year":"2010","journal-title":"Transl Res"},{"key":"2022022809300083600_R25","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.biochi.2013.06.020","article-title":"The stem cell secretome and its role in brain repair","volume":"95","author":"Drago","year":"2013","journal-title":"Biochimie"},{"key":"2022022809300083600_R26","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1007\/s00018-013-1290-8","article-title":"Mesenchymal stem cells secretome: A new paradigm for central nervous system regeneration?","volume":"70","author":"Teixeira","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"2022022809300083600_R27","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.biochi.2013.07.013","article-title":"The secretome of mesenchymal stem cells: Potential implications for neuroregeneration","volume":"95","author":"Paul","year":"2013","journal-title":"Biochimie"},{"key":"2022022809300083600_R28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2009.11.041","article-title":"Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease","volume":"1311","author":"Cova","year":"2010","journal-title":"Brain Res"},{"key":"2022022809300083600_R29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2202-11-52","article-title":"Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: Focusing on neuroprotective effects of stromal cell-derived factor-1alpha","volume":"11","author":"Wang","year":"2010","journal-title":"BMC Neurosci"},{"key":"2022022809300083600_R30","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1634\/stemcells.2005-0330","article-title":"Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease","volume":"24","author":"Weiss","year":"2006","journal-title":"Stem Cells"},{"key":"2022022809300083600_R31","first-page":"201","article-title":"Adult neurotrophic factor-secreting stem cells: A potential novel therapy for neurodegenerative diseases","volume":"11","author":"Sadan","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"2022022809300083600_R32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1517\/14712590903321439","article-title":"Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases","volume":"9","author":"Sadan","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"2022022809300083600_R33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1089\/scd.2008.0411","article-title":"Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease","volume":"18","author":"Sadan","year":"2009","journal-title":"Stem Cells Dev"},{"key":"2022022809300083600_R34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12015-014-9576-2","article-title":"Secretome of mesenchymal progenitors from the umbilical cord acts as modulator of neural\/glial proliferation and differentiation","volume":"11","author":"Teixeira","year":"2015","journal-title":"Stem Cell Rev"},{"key":"2022022809300083600_R35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13287-015-0124-z","article-title":"Do hypoxia\/normoxia culturing conditions change the neuroregulatory profile of Wharton Jelly mesenchymal stem cell secretome?","volume":"6","author":"Teixeira","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"2022022809300083600_R36","volume-title":"Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2004"},{"key":"2022022809300083600_R37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbr.2015.01.053","article-title":"A partial lesion model of Parkinson's disease in mice\u2013\u2013characterization of a 6-OHDA-induced medial forebrain bundle lesion","volume":"284","author":"Boix","year":"2015","journal-title":"Behav Brain Res"},{"key":"2022022809300083600_R38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1460-9568.2009.06878.x","article-title":"Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain","volume":"30","author":"Thompson","year":"2009","journal-title":"Eur J Neurosci"},{"key":"2022022809300083600_R39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0079-6123(09)17514-3","article-title":"Trophic factors therapy in Parkinson's disease","volume":"175","author":"Ramaswamy","year":"2009","journal-title":"Prog Brain Res"},{"key":"2022022809300083600_R40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuroscience.2008.03.048","article-title":"Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease","volume":"154","author":"Torres","year":"2008","journal-title":"Neuroscience"},{"key":"2022022809300083600_R41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jneumeth.2006.06.001","article-title":"Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model","volume":"158","author":"Monville","year":"2006","journal-title":"J Neurosci Methods"},{"key":"2022022809300083600_R42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fnbeh.2013.00175","article-title":"Rodent models of Parkinson's disease: Beyond the motor symptomatology","volume":"7","author":"Campos","year":"2013","journal-title":"Front Behav Neurosci"},{"key":"2022022809300083600_R43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0165-0270(91)90048-5","article-title":"The \u201cstaircase test\u201d: A measure of independent forelimb reaching and grasping abilities in rats","volume":"36","author":"Montoya","year":"1991","journal-title":"J Neurosci Methods"},{"key":"2022022809300083600_R44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","article-title":"Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates","volume":"192","author":"Bibbiani","year":"2005","journal-title":"Exp Neurol"},{"key":"2022022809300083600_R45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H","article-title":"Apomorphine: An underutilized therapy for Parkinson's disease","volume":"15","author":"Poewe","year":"2000","journal-title":"Mov Disord"},{"key":"2022022809300083600_R46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease\u2013\u2013Clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"2022022809300083600_R47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.expneurol.2013.03.017","article-title":"Chronic intranasal deferoxamine ameliorates motor defects and pathology in the \u03b1-synuclein rAAV Parkinson's model","volume":"247","author":"Febbraro","year":"2013","journal-title":"Exp Neurol"},{"key":"2022022809300083600_R48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pmic.201400221","article-title":"Short GeLC-SWATH: A fast and reliable quantitative approach for proteomic screenings","volume":"15","author":"Anjo","year":"2015","journal-title":"Proteomics"},{"key":"2022022809300083600_R49","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1021\/pr070492f","article-title":"Nonlinear fitting method for determining local false discovery rates from decoy database searches","volume":"7","author":"Tang","year":"2008","journal-title":"J Proteome Res"},{"key":"2022022809300083600_R50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2105-10-179","article-title":"Improved results in proteomics by use of local and peptide-class specific false discovery rates","volume":"10","author":"Sennels","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2022022809300083600_R51","doi-asserted-by":"crossref","first-page":"27791","DOI":"10.1038\/srep27791","article-title":"Modulation of the mesenchymal stem cell secretome using computer-controlled bioreactors: Impact on neuronal cell proliferation, survival and differentiation","volume":"6","author":"Teixeira","year":"2016","journal-title":"Sci Rep"},{"key":"2022022809300083600_R52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/187152712800792785","article-title":"A synopsis on the role of tyrosine hydroxylase in Parkinson's disease","volume":"11","author":"Tabrez","year":"2012","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2022022809300083600_R53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2005.11.026","article-title":"Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions","volume":"169","author":"Truong","year":"2006","journal-title":"Behav Brain Res"},{"key":"2022022809300083600_R54","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.5966\/sctm.2015-0023","article-title":"Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson's disease, focusing on cell distribution and neuroprotective and behavioral effects","volume":"4","author":"Cerri","year":"2015","journal-title":"Stem Cells Translational Medicine"},{"key":"2022022809300083600_R55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","article-title":"GDNF, NGF and BDNF as therapeutic options for neurodegeneration","volume":"138","author":"Allen","year":"2013","journal-title":"Pharmacol Ther"},{"key":"2022022809300083600_R56","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/sj.onc.1203551","article-title":"Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors","volume":"19","author":"Hirano","year":"2000","journal-title":"Oncogene"},{"key":"2022022809300083600_R57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0079-6123(08)01138-2","article-title":"Neuroprotection: VEGF, IL-6, and clusterin: The dark side of the moon","volume":"173","author":"Pucci","year":"2008","journal-title":"Prog Brain Res"},{"key":"2022022809300083600_R58","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/gt.2010.152","article-title":"VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease","volume":"18","author":"Xiong","year":"2011","journal-title":"Gene Ther"},{"key":"2022022809300083600_R59","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1460-9568.2004.03254.x","article-title":"Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease","volume":"19","author":"Yasuhara","year":"2004","journal-title":"Eur J Neurosci"},{"key":"2022022809300083600_R60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2005.05.027","article-title":"Neurorescue effects of VEGF on a rat model of Parkinson's disease","volume":"1053","author":"Yasuhara","year":"2005","journal-title":"Brain Res"},{"key":"2022022809300083600_R61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2015.04.001","article-title":"Dopaminergic differentiation of stem cells from human deciduous teeth and their therapeutic benefits for Parkinsonian rats","volume":"1613","author":"Fujii","year":"2015","journal-title":"Brain Res"},{"key":"2022022809300083600_R62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainres.2010.12.090","article-title":"Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease","volume":"1378","author":"Stahl","year":"2011","journal-title":"Brain Res"},{"key":"2022022809300083600_R63","first-page":"829","article-title":"[Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model]","volume":"70","author":"Takeda","year":"1995","journal-title":"Hokkaido Igaku Zasshi"},{"key":"2022022809300083600_R64","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1523\/JNEUROSCI.4601-04.2005","article-title":"Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta","volume":"25","author":"Baquet","year":"2005","journal-title":"J Neurosci"},{"key":"2022022809300083600_R65","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuroscience.2015.07.014","article-title":"GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease","volume":"303","author":"Hoban","year":"2015","journal-title":"Neuroscience"},{"key":"2022022809300083600_R66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nn1175","article-title":"Localized striatal delivery of GDNF as a treatment for Parkinson disease","volume":"7","author":"Kirik","year":"2004","journal-title":"Nat Neurosci"},{"key":"2022022809300083600_R67","first-page":"10","article-title":"GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease","volume":"9","author":"d\u2019Anglemont de Tassigny","year":"2015","journal-title":"Front Neuroanat"},{"key":"2022022809300083600_R68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3181\/0712-RM-329","article-title":"Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo","volume":"233","author":"Du","year":"2008","journal-title":"Exp Biol Med (Maywood)"},{"key":"2022022809300083600_R69","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0028-3908(99)00030-1","article-title":"Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: Role of antioxidation","volume":"38","author":"Chao","year":"1999","journal-title":"Neuropharmacology"},{"key":"2022022809300083600_R70","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2353\/ajpath.2010.100829","article-title":"Role of cystatin C in neuroprotection and its therapeutic implications","volume":"177","author":"D\u2019Adamio","year":"2010","journal-title":"Am J Pathol"},{"key":"2022022809300083600_R71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0306-4522(92)90105-B","article-title":"The prolonged presence of glia-derived nexin, an endogenous protease inhibitor, in the hippocampus after ischemia-induced delayed neuronal death","volume":"49","author":"Hoffmann","year":"1992","journal-title":"Neuroscience"},{"key":"2022022809300083600_R72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2012.08.006","article-title":"Galectin-1 for neuroprotection?","volume":"37","author":"Nonaka","year":"2012","journal-title":"Immunity"},{"key":"2022022809300083600_R73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/156652410791065354","article-title":"The neuroprotective role of PEDF: Implication for the therapy of neurological disorders","volume":"10","author":"Yabe","year":"2010","journal-title":"Curr Mol Med"},{"key":"2022022809300083600_R74","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3390\/ijms11082875","article-title":"The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's disease","volume":"11","author":"Falk","year":"2010","journal-title":"Int J Mol Sci"},{"key":"2022022809300083600_R75","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.expneurol.2007.05.012","article-title":"Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease","volume":"206","author":"Yasuda","year":"2007","journal-title":"Exp Neurol"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2016-0071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/2\/634\/42631575\/stcltm_6_2_634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/2\/634\/42631575\/stcltm_6_2_634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T14:55:18Z","timestamp":1718808918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/6\/2\/634\/6404726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":75,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,9,22]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2016-0071","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2016,9,22]]}}}